期刊
ORGANIC PROCESS RESEARCH & DEVELOPMENT
卷 25, 期 10, 页码 2177-2187出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.oprd.1c00082
关键词
impurity tracking and analytical data management; drug development; table of impurity carryover; structure elucidation group (SEG); active pharmaceutical ingredient (API)
The pharmaceutical company has major needs to track multiple reaction stages, calculate impurity carryover, and conduct structure dereplication for unknown impurities in the absence of standardized software. Mapping tools are in demand to consolidate API synthesis routes, link them with analytical data, reduce transcription errors, and maintain an audit trail throughout the process development lifecycle.
We present a perspective on drug development for the synthesis of an active pharmaceutical ingredient (e.g., agomelatine) within a commercial technology called Luminata and compare the results to the current method of consolidating the reaction data into Microsoft Excel. The Excel document becomes the ultimate repository of information extracted from multiple sources such as the electronic lab notebook, the laboratory information management system, the chromatography data system, inhouse databases, and external data. The major needs of a pharmaceutical company are tracking the stages of multiple reactions, calculating the impurity carryover across the stages, and performing structure dereplication for an unknown impurity. As there is no standardized software available to link the different needs throughout the life cycle of process development, there is a demand for mapping tools to consolidate the route for an API synthesis and link it with analytical data while reducing transcription errors and maintaining an audit trail.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据